Who
Jennifer Evans Stacey
Chief Legal Officer
Company insider
Files Form 4 as: Chief Legal Officer, Neogen; Director, Context Therapeutics; Officer, Galera Therapeutics; SVP, General Counsel & Secty, Antares Pharma; Executive VP & General Counsel, Auxilium Pharmaceuticals.
In numbers
- Trades disclosed
- 64
- Buys
- 0
- Sells
- 4
- Bought
- $0
- Sold
- $745K
- Companies
- 5
- Companies where not an officer
- 1
- First trade
- 16 Mar 2005
- Last trade
- 14 Aug 2026
- Last filed
- 14 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 14 Aug 2026filed 14 Aug 2026 | NEOG NeogenDiagnostics & Labs | SEC FORM 4 Code A | $450K38,627 at $11.65 | filing |
| 14 Aug 2026filed 14 Aug 2026 | NEOG Neogenoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —196,276 at $0.00 | filing |
| 14 Aug 2026filed 14 Aug 2026 | NEOG Neogenoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —196,276 at $0.00 | filing |
| 14 Aug 2026filed 14 Aug 2026 | NEOG NeogenDiagnostics & Labs | SEC FORM 4 Code A | $450K38,627 at $11.65 | filing |
| 24 Jun 2026filed 26 Jun 2026 | CNTX Context Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
| 24 Jun 2026filed 26 Jun 2026 | CNTX Context Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
| 1 May 2026filed 4 May 2026 | NEOG NeogenDiagnostics & Labs | SEC FORM 4 Code A | $375K39,349 at $9.53 | filing |
| 1 May 2026filed 4 May 2026 | NEOG Neogenoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —89,520 at $0.00 | filing |
| 1 May 2026filed 4 May 2026 | NEOG Neogenoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —89,520 at $0.00 | filing |
| 1 May 2026filed 4 May 2026 | NEOG NeogenDiagnostics & Labs | SEC FORM 4 Code A | $375K39,349 at $9.53 | filing |
| 12 Jun 2025filed 12 Jun 2025 | CNTX Context Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —123,500 at $0.00 | filing |
| 13 Jun 2024filed 14 Jun 2024 | CNTX Context Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 31 May 2023filed 31 May 2023 | CNTX Context Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 25 Feb 2023filed 28 Feb 2023 | Galera Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —135,000 at $0.00 | filing |
| 2 Jun 2022filed 3 Jun 2022 | CNTX Context Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 28 Feb 2022filed 2 Mar 2022 | Galera Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —75,000 at $0.00 | filing |
| 8 Oct 2021filed 12 Oct 2021 | Galera Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —130,000 at $0.00 | filing |
| 28 May 2015filed 1 Jun 2015 | Antares Pharma | SEC FORM 4 Code F | $5,3822,469 at $2.18 | filing |
| 28 May 2015filed 1 Jun 2015 | Antares Pharma | SEC FORM 4 Code A | —70,239 at $0.00 | filing |
| 28 May 2015filed 1 Jun 2015 | Antares Pharmaoption or derivative | SEC FORM 4 Code A | —142,550 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.